Researchers sought to determine whether the ALFA decision tool would be able to determine the prognosis for older patients with AML treated with intensive chemotherapy.
Researchers sought to determine whether CD-70 targeting CAR-T therapy would be an effective therapeutic strategy in patients with AML.
Researchers sought to determine whether APVO436 would have a favorable safety profile in treating patients with relapsed/refractory AML or MDS.
Researchers sought to determine whether the antisense oligonucleotide oblimersen can be added safely to conventional chemotherapy for older patients with AML.
Researchers sought to determine whether IRF4 expression is associated with an increased susceptibility to de novo AML and myelodysplastic syndrome.
Researchers sought to determine whether gilteritinib would have efficacy in patients with relapsed/refractory AML who had received prior TKI therapy.
Researchers sought to determine whether FLAG-IDA with venetoclax would yield MRD-negative composite complete remission in patients with newly diagnosed AML.
Researchers sought to determine whether for CD200 expression in leukemia stem cells would be associated with acute myeloid leukemia and therefore be a target for treatment.
Researchers sought to determine whether CXCL12 expression would be a predictor of poor prognosis in patients with acute myeloid leukemia.
A retrospective analysis sought to determine if adding leukapheresis would improve survival in AML patients with leukostasis.
